DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Pevonedistat

Generic Name: Pevonedistat

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₅O_₄S

CAS Number: 905579-51-3

Unique Ingredient Identifier: S3AZD8D215

Overview

Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.

Background

Pevonedistat has been used in trials studying the treatment of Lymphoma, Solid Tumors, Multiple Myeloma, Hodgkin Lymphoma, and Metastatic Melanoma, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML

Phase 2

Terminated

Posted: 2018/10/17

Sponsor:Milton S. Hershey Me...

A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors

Phase 1

Completed

Posted: 2018/04/03

Sponsor:Millennium Pharmaceu...

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Posted: 2018/03/27

Sponsor:

City of Hope Medical...

Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS

Phase 1

Completed

Posted: 2018/03/09

Sponsor:

Justin Watts, MD

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Phase 1

Terminated

Posted: 2017/12/29

Sponsor:Washington Universit...

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Approves Takeda's Exkivity as First Oral Therapy for EGFR Exon20 NSCLC

3 months ago

Takeda's Exkivity (mobocertinib) receives FDA approval as the first oral therapy specifically designed for NSCLC patients with EGFR exon20 insertion mutations after chemotherapy.

Advancements in Higher-Risk MDS Treatment Strategies Explored

8 months ago

Allogeneic transplantation remains the only curative option for high-risk myelodysplastic syndrome (HR-MDS) patients, but post-transplant relapse is still a problem.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy